High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

Completed · Phase 2

Conditions studied: Kidney Cancer, Melanoma (Skin)

In brief

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer or melanoma cells. PURPOSE: Phase II trial to study the effectiveness of high-dose interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer or melanoma.

Key facts

Study ID

NCT00003091

Run by

Hoag Memorial Hospital Presbyterian

People needed

40

Starts

1996-01-01

Expected to finish

2000-01-01

Last updated by the study team

2011-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
• Bloomington Hospital — Bloomington, Indiana, United States
• Baptist Regional Cancer Center - Knoxville — Knoxville, Tennessee, United States
• St. Joseph Regional Cancer Center — Bryan, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.